Company profile
Dianthus Therapeutics, Inc.
NASDAQ: DNTH · Healthcare · Biotechnology
#798 of 1,422 Healthcare companies by revenuebottom-quartile growth
EA Score
49DFH 47DQ 48GM —SS 64
v0.1 · 55/100 weight · provisional
↑ Altman-Z, balance-sheet leverage · ↓ Piotroski F, operating margin
Methodology →Revenue TTM
$1.3M
Rev growth YoY (TTM)
-79.5%
Net income (FY)
-$162.3M
Employees
92
as of 2026-08-07
Market cap
$4.6B
as of 2026-08-07
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$2.0M$2.0M2025
Net income-$162.3M-$162.3M2025
Operating income-$177.9M-$177.9M2025
Total assets$530.9M$530.9M2025
Liabilities$37.5M$37.5M2025
Equity$493.4M$493.4M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY19
FY19
FY19
FY24
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
License100%
By geography
Not disclosed.
The read
What is Dianthus Therapeutics, Inc.’s revenue?
Dianthus Therapeutics, Inc. booked $2.0M in FY2025 revenue, contracting 67% year over year — slower than 85% of Healthcare companies we track, at a -7973.3% net margin.
Peers · Healthcare
20/20 Biolabs Inc.29DHumacyte, Inc.27DNutriband Inc.52DCocrystal Pharma, Inc.31DSagimet Biosciences Inc.36DOramed Pharmaceuticals Inc.61CNeighbors
New York →Key facts
CEOMarino Garcia
SectorHealthcare
IndustryBiotechnology
HeadquartersNew York, NY
ExchangeNASDAQ: DNTH
Employees92
IPO date2018-06-21
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.